Article Sidebar
Date Published:
23/12/2024
Abstract Views: 44
Views pdf: 40
Views pdf: 40
Issue
Section
Các bài báo
How to Cite
Phạm, T. H., & Mai, T. H. (2024). CASE REPORT: THE SECOND-LINE TREATMENT WITH IMMUNOTHERAPY IN ADVANCED STAGE HEPATOCELLULAR CARCINOMA PATIENT. Vietnam Medical Journal, 545(3). https://doi.org/10.51298/vmj.v545i3.12368
CASE REPORT: THE SECOND-LINE TREATMENT WITH IMMUNOTHERAPY IN ADVANCED STAGE HEPATOCELLULAR CARCINOMA PATIENT
Main Article Content
Abstract
Overview: Hepatocellular carcinoma is a common malignant cancer with high risk of incidence and mortality, often diagnosed at an advanced stage, with poor prognosis. With advanced stage hepatocellular carcinoma, the main treatment is systemic therapy including targeted therapy and immunotherapy. Case report: A 73-year-old male patient, diagnosed with hepatocellular carcinoma who progressed after Sorafenib regimen, was treated with systemic therapy with Pembrolizumab at Friendship Hospital.
Article Details
Keywords
Hepatocellular carcinoma, systemic therapy, pembrolizumab.
References
1. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10(1): 25-34. doi:10.1016/S1470-2045 (08) 70285-7
2. Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol Off J Am Soc Clin Oncol. 2020;38(3): 193-202. doi:10.1200/ JCO.19.01307
3. Global Cancer Statistics 2020: GLOBOCAN. Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries - Sung - 2021 - CA: A Cancer Journal for Clinicians - Wiley Online Library. Accessed October 2, 2022. https:// acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21660
4. Qin S, Chen Z, Fang W, et al. Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study. J Clin Oncol. 2022;40(4_suppl):383-383. doi:10.1200/JCO.2022.40.4_suppl.383
5. Shlomai A, Leshno M, Goldstein DA. Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib—A cost-effectiveness analysis. PLoS ONE. 2018;13(11): e0207132. doi:10.1371/ journal.pone.0207132
6. Yau T, Park JW, Finn RS, et al. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2019;30: v874-v875. doi:10.1093/annonc/ mdz394.029
7. Zhu AX, Finn RS, Cattan S, et al. KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. J Clin Oncol. 2018;36(4_suppl):209-209. doi:10.1200/JCO.2018.36.4_suppl.209
8. Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282-296. doi:10.1016/S1470-2045(18)30937-9
2. Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol Off J Am Soc Clin Oncol. 2020;38(3): 193-202. doi:10.1200/ JCO.19.01307
3. Global Cancer Statistics 2020: GLOBOCAN. Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries - Sung - 2021 - CA: A Cancer Journal for Clinicians - Wiley Online Library. Accessed October 2, 2022. https:// acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21660
4. Qin S, Chen Z, Fang W, et al. Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study. J Clin Oncol. 2022;40(4_suppl):383-383. doi:10.1200/JCO.2022.40.4_suppl.383
5. Shlomai A, Leshno M, Goldstein DA. Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib—A cost-effectiveness analysis. PLoS ONE. 2018;13(11): e0207132. doi:10.1371/ journal.pone.0207132
6. Yau T, Park JW, Finn RS, et al. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2019;30: v874-v875. doi:10.1093/annonc/ mdz394.029
7. Zhu AX, Finn RS, Cattan S, et al. KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. J Clin Oncol. 2018;36(4_suppl):209-209. doi:10.1200/JCO.2018.36.4_suppl.209
8. Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282-296. doi:10.1016/S1470-2045(18)30937-9